Background: Alterations of the p53 (also called TP53) gene are one of the most common abnormalities in gliomas. We have previously reported that restoration of wild-type p53 protein function in glioma cells results in programmed cell death (apoptosis). Since p53 functions are mediated by genes that directly control the tumor suppressor effect of the p53 protein, understanding the relationship between p53 and p53-related genes in glioma cells will aid in the design of more rational treatment strategies for brain tumors. Purpose: We conducted this study to examine the timing of the p53-mediated events preceding apoptosis. More specifically, we undertook this work to characterize the genetic and cell cycle-related factors that may increase the resistance of glioma cells to p53-induced apoptosis. Methods: Two human glioma cell lines (U-251 MG and U-373 MG) that express mutant p53 protein and two (U-87 MG and EFC-2) that express wild-type p53 protein were used. Replicationdeficient adenovirus was utilized as an expression vector to transfer exogenous p53 and p21 complementary DNAs into the glioma cells; control cells were infected with the viral expression vector alone. To monitor gene transfer and the expression of exogenous genes (as well as the expression of endogenous genes), we used western blot analyses and immunohistochemistry analyses. Flow cytometry studies of cellular DNA content were performed to determine the cell cycle phenotype of the glioma cells before and after treatment. Results: p53-mediated apoptosis was preceded by elevation in the levels of the p21 (cell cycle-related) and Bax (apoptosis-related) proteins. In addition, cell cycle analyses showed that glioma cells were arrested in the G 2 phase before undergoing cell death. Transfer of p21 induced
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Therapeutic strategies designed to restore wild-type p53 protein activity in cancer cells are particularly appealing, since the p53 tumor suppressor gene (also known as TP53) is the most frequent target for genetic alterations in human cancer (1, 2) . Although the p53 anticancer effect is well documented, the underlying mechanisms and the interrelation among the different genes involved in the control of programmed cell death (apoptosis) are still under intense examination. In this regard, the ability of p53 to activate transcription indicates that genes induced by p53 may mediate its biologic role as a tumor suppressor (3). The p53 protein up-regulates (i.e., increases) the expression of at least two genes, p21 and bax, whose encoded products are able to regulate growth arrest and apoptosis. The p53 protein directly induces the expression of the p21 gene (4) . The p21 protein is a negative regulator of cell growth involved in the control of the G 1 (5) and the G 2 (6) cell cycle checkpoints by binding and inhibiting the function of cyclin/cyclin-dependent kinase complexes (6, 7) . The p53 protein also transcriptionally activates the death gene bax (8) . Bax is an apoptosis-promoting member of the Bcl-2 family whose function depends on the presence of and heterodimerization with Bcl-2 or other Bcl-2 family members (9) . In addition, other factors different from p53 and p53-related genes may modify the susceptibility of cells to undergo apoptosis. In this regard, the retinoblastoma gene product Rb may have an anti-apoptosis role under certain circumstances (10) . Therefore, although p53-mediated growth arrest and apoptosis have been considered two p53-dependent functions, there is no definitive evidence that proves this hypothesis (11) . Furthermore, it was recently reported that p21 protects differentiating myoblasts, neuroblasts, and colon cancer cells from undergoing apoptosis (12) (13) (14) .
Mutations of p53 are present in more than 30% of gliomas, which are the most common tumors of the brain, and constitute an early genetic event, suggesting that abnormalities of p53 are involved in development of gliomas (15, 16) . It is interesting that the incidence of p53 mutations in glioma cell lines is similar to that reported for primary brain tumors, indicating that these cell lines are useful tools for investigating the antineoplastic role of the wild-type p53 gene in gliomas (17) . In a previous study (18) , we demonstrated that it is possible to overexpress an exogenous wild-type p53 complementary DNA (cDNA) in a bulk population of human glioma cells by using the recombinant replicationdeficient adenovirus vector Ad5CMV-p53. The restoration of the function of wild-type p53 in human glioma cells expressing mutant p53 induced apoptosis, as assessed by acridine orange nuclear staining, electron microscopy, and flow cytometry assays. In contrast, expression of exogenous p53 in human glioma cells containing a wild-type p53 gene inhibited cell growth but did not induce apoptosis (18) .
Knowledge of the p53 pathway may be crucial for the understanding of the pathogenesis of gliomas and may help to increase the vulnerability of these cancer cells to therapy. In addition, detailed examination of the p53 pathway may have extraordinary importance to the ascertainment of why certain cancer cells are resistant to treatments directed to trigger apoptosis.
The purpose of our study was to evaluate the molecular and cell cycle-related events that precede the entry of cells into apoptosis, in order to detect the factors that potentiate the tumor suppressor function of p53 and to recognize those that favor the acquisition of an anti-apoptotic phenotype.
Materials and Methods
Human glioma cell lines and culture conditions. The human glioma cell lines U-251 MG, U-373 MG, and U-87 MG were purchased from the American Type Culture Collection, Rockville, MD. The human glioma cell line EFC-2 was established from a glioblastoma multiforme at the Department of NeuroOncology, The University of Texas M. D. Anderson Cancer Center (19) . The cells were cultured in Dulbecco's modified Eagle medium/F12 medium (1:1, vol/vol) supplemented with 10% fetal calf serum (HyClone Laboratories, Inc., Logan, UT) in a humidified atmosphere containing 5% CO 2 at 37°C. U-251 MG and U-373 MG have a mutation in codon 273 of the p53 gene (20, 21) and cannot transactivate a reporter gene containing a p53-responsive transcriptional promoter (22) . The endogenous p53 gene in U-87 MG cells is known to have wild-type sequence in exons 2 through 11 (22) ; in EFC-2 cells, its sequence is known to be of the wild type in exons 5 through 8 (18) .
Generation of recombinant adenovirus and conditions of infection. The construction, generation, and characterization of the recombinant-deficient adenovirus vectors that we used were explained in detail elsewhere (23, 24) . Ad5CMV-p53 and Ad5CMV-p21 (supplied by Jack Roth, Department of Thoracic Surgery, The University of Texas M. D. Anderson Cancer Center) carry a human cytomegalovirus promoter, the simian virus 40 polyadenylation signal, and p53 or p21 cDNAs, respectively, inserted into the E1-deleted region of the modified adenovirus 5. Ad5CMV-pA, an adenovirus vector carrying a minicassette including the human cytomegalovirus promoter and the simian virus 40 polyadenylation signal only, was used as virus control. The cell lines were infected as reported previously (18) . For these experiments, we used a multiplicity of infection (further defined as the ratio of the number of infectious virions to the number of susceptible cells) of 100 units. Control cells were infected with the virus control.
Western blot analysis. Total cell lysates were prepared by incubating cells at different time points after the infection with Ad5CMV-p53, Ad5CMV-p21, or Ad5CMV-pA in RIPA buffer (150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 20 mM EDTA, and 50 mM Tris [pH 7.4]) for 1 hour at 4°C. Twenty micrograms of protein from each sample was subjected to electrophoresis in 15% acrylamide (for p53, p21, Bax, and Bcl-2) or 7.5% acrylamide (for Mdm2) gels in the presence of Tris-glycine buffer gel and then electrophoretically transferred to a nitrocellulose membrane (Schleicher and Schuell, Inc., Keene, NH). The membrane was incubated with Blotto-Tween (5% nonfat milk, 0.05% Tween 20, 0.9% NaCl, and 50 mM Tris [pH 7.5]) to block nonspecific antibody binding. It was then incubated with the primary antibodies mouse anti-human p53 DO-7 (Dako Corp., Carpinteria, CA), rabbit anti-human p21 C-19 (Santa Cruz Biotechnology Inc., CA), rabbit anti-human Bax N-20 (Santa Cruz Biotechnology Inc.), mouse anti-human Bcl-2 100 (Santa Cruz Biotechnology Inc.), mouse anti-human Mdm2 SMP 14 (Santa Cruz Biotechnology Inc.), or mouse anti-human ␤-actin monoclonal antibody (Amersham Corp., Arlington Heights, IL) and with a secondary antibody, either horseradish peroxidase-conjugated goat anti-mouse or donkey anti-rabbit immunoglobulin G (Amersham Corp). The membranes were developed according to Amersham's enhanced chemiluminescence protocol. Changes in the expression of the proteins were analyzed by densitometer.
DNA content flow cytometry studies. The procedure and technology used have already been described (18) . All measurements were made with an EPICS profile flow cytometer (Coulter Corp., Hialeah, FL) equipped with an air-cooled argon ion laser emitting 488 nm at 15 mW. A minimum of 10 000 events per sample was analyzed, and fluorescein isothiocyanate fluorescence was collected by use of a 525BP filter. The mean peak fluorescence was determined for each histogram. The sub-G 1 population (i.e., the cells with less than a diploid DNA content) was isolated from the general cell population before the percentages of cells in the G 0 /G 1 , S, and G 2 /M phases were determined. The Cytologic (Coulter Corp.) and Multicycle (Phoenix Flow System, San Diego, CA) computer programs were used for data analysis.
Mitotic index. Cells were plated and cultured in chamber slides. After fixation with acetone, the cells were stained with hematoxylin. The mitotic fraction was determined by counting the number of cells in metaphase among, at least, 1000 cells from each sample. Three separate experiments were performed.
Determination of cell growth rate. Glioma cells were seeded in six-well culture plates for 20 hours before viral infection. The cells were infected with either Ad5CMV-p21 or Ad5CMV-pA at a multiplicity of infection of 100 plaque-forming units per cell. Culture medium was used for mock infection. Triplicate dishes of each treatment were counted at regular intervals until the 8th day after infection. The viability of the cells was assessed by use of trypan blue dye staining.
Immunocytochemical assay. After 48 hours, U-87 MG and EFC-2 cells infected with Ad5CMV-p53 or Ad5CMV-pA were fixed with acetone and pro-cessed by following the Vector Elite ABC kit protocol (Vector Laboratories, Inc., Burlingame, CA). Anti-human p53 DO-7, diluted 1:50 in blocking serum buffer (Vector Laboratories, Inc.), was used as a primary antibody. The chromogen was diaminobenzidine (Vector Laboratories, Inc.). The cells were counterstained with Harris hematoxylin (Sigma Chemical Co., St. Louis, MO).
Results

G 2 Arrest and Apoptosis of U-251 MG and U-373 MG Cells Induced by Wild-Type p53
The recombinant replication-deficient adenovirus Ad5CMV-p53 was used to investigate the specific effect of wild-type p53 protein on cell cycle control and apoptosis in two human glioma cell lines, U-251 MG and U-373 MG, expressing mutant p53 protein. Ad5CMV-p53 was previously shown to infect 80%-100% of glioma cells at a single dose of 100 multiplicity-ofinfection units (18) . The newly expressed p53 protein was detected by western blot at 8 hours and peaked at 72 hours after infection (18) . After p53 coding sequence transfer to U-251 MG glioma cells, the level of the p53 protein was at least sevenfold higher (mean ± standard deviation ‫8.7ס‬ ± 0.6) than the endogenous mutant p53 protein (Fig. 1) .
After infection, cells were fixed at 0, 20, 25, 30, 36, and 48 hours and analyzed with a fluorescence-activated cell sorter, and the percentage of cells in every phase of the cell cycle was determined by their DNA content. These experiments revealed that the percentage of cells in G 2 /M among Ad5CMV-p53-infected cells was greater than that among virus control-infected cells and increased with time (Fig. 2, A) . By 20-25 hours after the infection, 33.2% ± 2.9% (mean value ± standard deviation) of the Ad5CMV-p53-infected U-251 MG cells were in G 2 /M versus 10.5% ± 1.7% of the virus control-infected cells. The G 2 /M population increased progressively; 10 hours later (30 hours after infection with virus containing p53), 52.8% ± 7.6% and 54.2% ± 6.2% of the Ad5CMV-p53-infected U-251 MG and U-373 MG cells, respectively, were in G 2 /M versus 18.9% ± 4% and 12.2% ± 7%, respectively, of the virus control-infected cells. After that point, the G 2 /M peak became flattened, and the cell viability decreased. Moreover, as we have previously reported (18) , the cells morphologically resembled cells in apoptosis; i.e., they lost cell-cell contact, their cytoplasm shrank, and their nuclei became fragmented. Forty-eight hours after infection, 52.6% ± 16.3% and 47.7% ± 10.5% of the Ad5CMV-p53-infected U-251 MG and U-373 MG cells, respectively, were in sub-G 1 versus 7.3% ± 2.6% and 5.4% ± 3.2%, respectively, of the virus control-infected cells. The sub-G 1 population is indicative of cell death and is considered to be a marker of apoptosis (25) . In addition, we previously reported that, after Ad5CMV-p53 infection, the percentage of cells in sub-G 1 among U-251 MG cells was similar to the percentage of cells in apoptosis, as assessed by the terminal deoxynucleotidyltransferase method (18) 
We next calculated the mitotic index to determine whether the U-251 MG cells were arrested in the G 2 or M phase. Thirty hours after Ad5CMV-p53 infection, the percentage of cells in the M phase was less than 1.9% ± 0.6% for infected cells and 1.3% ± 0.6% for virus control-infected cells. Therefore, the flow cytometry and mitotic index analyses indicated that the Ad5CMV-p53-infected cells were arrested in the G 2 phase of the cell cycle.
Activation of the p53-Responsive Genes p21 and bax in U-251 MG and U-373 MG Cells After Ad5CMV-p53 Infection A previous study (4) showed that wild-type p53 is able to activate the p21 promoter. To test whether exogenous wild-type p53 up-regulated p21 in these two glioma cell lines, we measured the p21 protein levels after a single dose of 100 multiplicity-of-infection units of the Ad5CMV-p53. Western blot analysis showed that there was an elevation in the cellular levels of p21 after p53 expression in U-251 MG cells (Fig. 3) and U-373 MG cells (data not shown). The p21 levels began to increase within 10 hours after infection and were at least sixfold higher than the basal levels in both cell lines by 15 hours. Levels of p21 protein remained elevated until most of the cells had died.
Because the up-regulation of p21 and the G 2 arrest were temporally related events, we examined whether p21 blocked the progression of the cells through this checkpoint. To test this hypothesis directly, we transferred p21 cDNA into these two cell lines by using 100 multiplicity-of-infection units of the adenovirus vector Ad5CMV-p21. Flow cytometry analyses of the Ad5CMV-p21-infected cells showed accumulation of the cells in the G 2 phase (Fig. 4) . Thirty hours after the Ad5CMV-p21 infection, the percentage of cells in the G 2 population was 30.8% ± 8.9% (mean ± standard deviation) in U-251 MG cells and 29.6% ± 3.5% in U-373 MG cells versus 8.1% ± 4.6% and 17.1% ± 2.6%, respectively, in virus control-infected cells (Fig.  4) . In contrast to Ad5CMV-p53-infected cells, Ad5CMV-p21-infected cells did not display any signs of apoptosis after accumulation in G 2 , as assessed by flow cytometry (Fig. 4) and light microscopy (Fig. 5) .
Since the elevation of Bax protein levels is temporally related to apoptosis (26) and p53 regulates bax gene expression (8), we sought to determine whether Bax protein levels increased before the onset of apoptosis. Western blot analyses of the levels of specific proteins over time showed that the increase in the levels of Bax in U-251 MG and U-373 MG cells occurred 25 hours after infection of the cells with Ad5CMV-p53. Bax protein levels remained elevated until cell death occurred (Fig. 3) . At that moment, a highly reproducible threefold increase in Bax protein levels was detected. A similar increase in Bax protein levels has been observed immediately before ␥ radiation-induced apoptosis in other cell types (26) . Taken together, these data indicated that the induction of p21 protein and G 2 arrest were early events following p53 gene transfer and that the induction of Bax protein synthesis and the entry of cells into apoptosis occurred later.
G 1 Arrest of EFC-2 and U-87 MG Cells by Exogenous Wild-Type p53 Transfer
In contrast to the p53 effect observed in cells expressing mutant p53, Ad5CMV-p53 infection of U-87 MG and EFC-2 cells, which possess a wild-type p53 gene, resulted in the accumulation of cells in the G 1 phase. The cell cycle distribution was assessed after p53 transfer by DNA content flow cytometry analyses (Fig. 2, B) . Thus, 30 hours after treatment, 81.9% ± Fig. 3 . Immunoblot analyses of Bax and p21 expression after p53 transfer. Cellular proteins were extracted at the indicated time points after Ad5CMV-p53 infection. A) In the mutant p53 cell line U-251 MG, both the p21 and Bax proteins were induced. B) In the wild-type p53 cells U-87 MG and EFC-2, p21 was induced but Bax protein was not. In addition, the level of expression of the ␤-actin protein was used as a further control to verify loading of equal amounts of protein samples.
3.4% (mean ± standard deviation) of the Ad5CMV-p53-infected U-87 MG cells and 74.1% ± 5.6% of the Ad5CMV-p53-infected EFC-2 cells were in G 1 versus 56.2% ± 9.5% and 49% ± 5.1%, respectively, of the virus control-infected cells. Moreover, there was a substantial reduction in the population of cells in S phase in comparison with the virus control-infected cells: 6.3% ± 0.7% of the Ad5CMV-p53-infected U-87 MG cells and 9.6% ± 2.9% of the Ad5CMV-p53-infected EFC-2 cells versus 24.06% ± 5.3% and 24.2% ± 2.8%, respectively, of the control virusinfected cells were in S phase. Ad5CMV-p53-mediated cell death assessed by trypan blue dye exclusion or flow cytometry measurement of DNA content was not observed in these cell lines (18) .
To determine if the G 1 arrest was caused by p21, we transferred p21 cDNA (i.e., its complete coding sequence) into U-87 MG and EFC-2 cells (Fig. 4, B) . The newly expressed p21 induced G 1 arrest. Thus, 82.6% ± 5.2% and 75% ± 5.7% of the Ad5CMV-p21-infected U-87 MG and EFC-2 cells, respectively, versus 55.5% ± 9.6% and 55.1% ± 9.2%, respectively, of the virus control-infected cells were in the G 1 phase 30 hours after infection. In addition, the percentage of cells in the S phase decreased: 5.9% ± 0.5% of the Ad5CMV-p21-infected U-87 MG cells versus 24.2% ± 5.4% of the control virus-infected cells and 12.2% ± 0.9% of the Ad5CMV-p21-infected EFC-2 cells versus 25.5% ± 4.6% of the virus control-infected cells (Fig. 4, B) .
Basal Levels of Mdm2 and Bcl-2 Proteins in Wild-Type p53 and Mutant p53 Human Glioma Cells
In addition to p53 mutations, overexpression of Mdm2 (27) and nuclear exclusion of the p53 protein (28) are responsible for p53 inactivation in some gliomas. In the four glioma cell lines we tested, Mdm2 protein was barely detectable (Fig. 6) and was induced to similar levels in all four cell lines after p53 transfer (data not shown). Immunohistochemical analysis of U-87 MG and EFC-2 cells 48 hours after Ad5CMV-p53 infection showed nuclear localization of the exogenous p53 protein in more than 80% of the glioma cells (data not shown). Cells infected with Ad5CMV-pA did not show p53 staining. In addition, we examined the basal levels of Bax and Bcl-2 proteins and the ratio of Bax to Bcl-2, which has been related to resistance to apoptosis (29) , and found no differences between wild-type p53 and mutant p53 cells (Fig. 6) . Finally, western blot analyses performed 30 hours after infection with the Ad5CMV-p53 showed that the levels of p53 protein were similar in the four cell lines (data not shown); thus, we ruled out the possibility that different levels of the exogenous p53 protein in the mutant and wild-type p53 cell lines were responsible for the different p53-mediated effects.
Induction of p21 but not Bax After p53 Overexpression in U-87 MG and EFC-2 Cells
Asynchronous populations of U-87 MG and EFC-2 were treated with 100 multiplicity-of-infection units of Ad5CMV-p53, and protein extracts were isolated at several points. The levels of p21 protein increased within 12 hours after Ad5CMV-p53 infection, were five times greater than the basal level at 24 hours, and remained at similar levels over the 36-hour time course. We next examined the induction of Bax after p53 transfer. In these two wild-type p53 glioma cells, Bax protein levels, assessed by western blot, remained unchanged, which indicated that Bax expression was not induced after the forced expression of exogenous wild-type p53 (Fig. 3) . Further studies must be performed to ascertain whether these cells harbored abnormalities upstream or downstream of p53.
Partial Protection From p53-Mediated Apoptosis by Expression of Exogenous p21
To better understand the role that p21 plays in the p53-mediated apoptosis pathway in gliomas, we infected U-251 MG and U-373 MG cells first with Ad5CMV-p21 and then 3 days later with Ad5CMV-p53. Forty-eight hours after the transfer of the wild-type p53 cDNA, there were substantially fewer apoptotic cells in comparison with the large number of control cells (which were infected first with Ad5CMV-pA and 3 days later with Ad5CMV-p53) detached from the dish. These observations were corroborated by flow cytometry analyses in both glioma cell lines (Table 1) . Cultures first infected with Ad5CMV-p21 had 50% fewer cells in apoptosis 48 hours after Ad5CMV-p53 infection than cells infected first with the virus control (Fig. 7) . These results may be underestimated because it is possible that not every cell received both the p53 and the p21 genes. We next determined whether the modification in the growth characteristics mediated by expression of the exogenous p21 was present when the cells were exposed to Ad5CMV-p53. Cell cycle analyses showed that Ad5CMV-p21-treated U-373 MG cells were accumulated in the G 2 phase (32.1% and 32% in two separate experiments), with respect to the virus control-infected cells (19% and 18.9%, respectively), at the moment of Ad5CMV-p53 infection. Moreover, at that time, the growth of U-251 MG and U-373 MG cell lines was inhibited by 56.8% ± 6.4% (mean ± standard deviation) and 54.9% ± 7.4%, respectively. In addition, treated cells exhibited an increase in size, compared with the size of the parental cells, as well as other morphologic changes compatible with growth arrest (Fig. 5) . Further studies will be necessary to define the characteristics of the hypothetical p53/p21 expression balance that would modulate apoptosis and to determine whether the p21 anti-apoptotic effect depends on its cell growth-regulatory properties (14) .
Discussion
In this study, we demonstrated a link between overexpression of the p21 protein in glioma cells and acquisition of resistance to p53-mediated apoptosis. This function of the p21 protein has important implications in both neoplastic transformation and design of treatment strategies for brain tumors. The adenoviral vector used in our investigation to efficiently express exogenous wild-type p53 (Ad5CMV-p53) is an excellent tool because of its ability to infect a wide spectrum of cancer cells, including glioma cells, and its clinical relevance inasmuch as Ad5CMV-p53 is currently being used in human clinical trials (1) . The results of our study and a previous study (18) indicated that p53 status determines the susceptibility of gliomas to treatment involving restoration of wild-type p53 activity. Overexpression of an exogenous wild-type p53 in mutant p53 cells abolished the neoplastic phenotype by consecutive cell cycle arrest and apop- Fig. 6 . Levels of Bcl-2, Bax, and Mdm2 proteins in U-373 MG (mutant p53), U-251 MG (mutant p53), U-87 MG (wild-type p53), and EFC-2 (wild-type p53) glioma cells. Cell lysates were prepared from the parental glioma cells, and equal aliquots of 20 g were incubated with the primary antibodies anti-human Bcl-2, Bax, and Mdm2 proteins. C ‫ס‬ cell lysate from a cell line that overexpresses Mdm2, used as a positive control. The level of the ␤-actin protein was used as a loading control. tosis. Transfer of wild-type p53 into cells expressing endogenous wild-type p53, however, did not induce apoptosis. Induction of apoptosis may indicate that p53 has a primary role in the genesis of gliomas expressing a mutant p53 gene. In such tumors, restoration of p53 activity would lead to the accurate detection of the genetic abnormalities and the trigger of apoptosis as reported for other systems (14, 30, 31) . The different p53 effects suggest that there are different pathways of glioma tumorigenesis and point out the opportunity for designing more selective therapeutic strategies by taking advantage of the increased vulnerability of mutant p53 cells.
Our data support a model in which p53 induces growth arrest by activation of p21 (3) (4) (5) (6) . In mutant p53 glioma cells, overexpression of p53 produced mainly G 2 arrest. Although p53 has been reported to induce G 1 arrest (32, 33) , the accumulated evidence that p53 is involved in blocking cells at G 2 /M in addition to G 1 (6, 14, (34) (35) (36) (37) (38) is consistent with our results. In addition, p21 is found in several cyclin kinase complexes, including those prevalent in G 2 (7) . However, it is noteworthy that, although introduction of p21 also resulted in G 2 arrest, the p21 effect was not as dramatic as the p53 effect, suggesting that factors other than p21 may collaborate in the p53-mediated G 2 arrest. In addition to its role in G 1 and G 2 , the p53 protein is involved in controlling both the duration of and the exit from the G 2 block (39). It is interesting that, at the time of apoptosis, the number of cells in G 2 decreased significantly, suggesting that the cells that underwent apoptosis were cycling (40) . In our model, p53 would have the ability to produce two different signals, one to raise and the other to override the G 2 block. The ability of p53 and p21 to induce G 1 arrest was also confirmed by the experiments with wild-type p53 glioma cells. These cells experienced G 1 arrest and did not undergo apoptosis after overexpression of the exogenous p53. The experiments with wild-type p53 cells ruled out three common mechanisms of indirect p53 inactivation, including nuclear exclusion and overexpression of Mdm2 and Bcl-2 proteins. In these two glioma cell lines, wild-type p53 (either endogenous or exogenous) may therefore be unable to detect DNA damage or to activate the apoptosis mechanism. In addition, it might also be that, in wild-type p53 cells, the p21-mediated growth arrest was dominant over the p53-mediated apoptosis (14) .
Exogenous p53 increased the expression of Bax in mutant p53 glioma cells. The observed elevation in Bax levels was related temporally to the commitment of cancer cells to apoptosis, suggesting that Bax might be one of the mediators of p53-related apoptosis in gliomas. Further studies based on transferring the bax coding sequence to glioma cells may elucidate the exact role that Bax protein plays in p53-induced apoptosis in malignant brain tumors.
The sequence of p53-mediated events in mutant p53 glioma cells may indicate that p21-mediated growth arrest and apoptosis were dependent functions. Several lines of evidence, however, suggest that these two p53 effects were related but not necessarily dependent: (a) In this study, we showed that pretreatment with p21 induced growth arrest and protected cells expressing an exogenous wild-type p53 from undergoing apoptosis; (b) inactivation of p21 by homologous recombination prevented wildtype p53 colon cancer cells from arresting in the G 1 and G 2 phases and led them to apoptosis after the transfer of an exogenous wild-type p53 (14) ; (c) a previous report (12) has also shown that expression of p21 confers resistance to apoptosis on differentiating myocytes; and (d) consistent with this observation, antisense oligonucleotides to p21 enhance cell death by apoptosis in differentiating neuroblastoma cells (13) .
Additional data indirectly supporting the anti-apoptotic p21 effect are based on the inhibition of apoptosis by the Rb protein.
Since the p21 protein exerts its functions through inhibiting phosphorylation of Rb, it is relevant to mention that Rb expression prevented sarcoma and cervical cancer cells from undergoing apoptosis after irradiation (41) and after p53 expression (10), respectively. Taken together, these observations indicate that the p53 and p21 genes may play opposite roles in the control of apoptosis and that it is possible that the p53-mediated induction of p21 serves to modulate the timing and intensity of the p53 apoptotic signals. An imbalance in the regulatory coupling of p21-mediated growth arrest and p53-induced apoptosis may diminish cancer cell death via apoptosis.
Because p21 has been found to be overexpressed in gliomas (42) , our data acquire clinical relevance. Our study results support the hypothesis that high levels of p21 protein in glioma cells might render these cells more resistant to apoptosis-inducing treatments (43) , influencing negatively the outcome of gliomas overexpressing this cell growth regulator. Abnormally high expression of p21 could therefore contribute both to glioma progression by facilitating the growth of cells with sustained genomic instability and to treatment resistance by diminishing the cytocidal effect of anticancer therapies that activate p53-induced apoptosis (44) (45) (46) . Taken together, our data suggest that p21, like p16 (47), might be utilized in chemoprevention strategies. Thus, the transfer of p21 to nontumor cells might protect them from drug or radiation therapy.
